Cardiometabolic & Bone

Cat. No.

A53634

CAS No.

2929240-20-8

Delpacibart zotadirsen

Synonyms: Del-zota; AOC 1044

Delpacibart zotadirsen is an antibody oligonucleotide conjugate that targets the transferrin receptor 1 (TfR1). This innovative reagent is designed to deliver phosphorodiamidate morpholino oligomers (PMOs) specifically to skeletal muscle and heart tissue, facilitating the skipping of exon 44 in the dystrophin gene to promote the production of near-full-length dystrophin. Delpacibart zotadirsen is a valuable tool for investigating myotonic dystrophy type 1 (DM1) and advancing research in therapeutic approaches for muscle disorders.

Cat. No.

A69526

CAS No.

3062245-47-7

Corveldebart

Corveldebart is an anti-ANGPTL4 monoclonal antibody, characterized as an IgG1-kappa isotype. This reagent specifically targets angiopoietin-like 4 (ANGPTL4), a protein involved in the regulation of lipid metabolism and angiogenesis. Corveldebart is essential for research applications focused on cardiovascular disease, obesity, and related metabolic disorders, enabling the exploration of ANGPTL4's role in these physiological processes.

Cat. No.

A84979

CAS No.

3035422-95-5

Asedebart

Synonyms: LuAG13909

Asedebart is a CHO-expressed human antibody that specifically targets Adrenocorticotropic hormone (ACTH) and functions as an antagonist to inhibit the binding of ACTH to its receptor. With a molecular weight of approximately 145 kDa, comprising a huIgG1 heavy chain and huκ light chain, Asedebart facilitates studies into inflammatory diseases, including psoriasis and ulcerative colitis. Its application as a research reagent offers valuable insights into ACTH-related pathways and therapeutic interventions.

Cat. No.

AT0019

CAS No.

1407495-04-8

Ralpancizumab

Ralpancizumab is a selective monoclonal antibody inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), a regulator of LDL receptor degradation. While primarily studied in cardiovascular research, Ralpancizumab is also being investigated for its potential role in hemorrhagic stroke models, offering insights into lipid metabolism and vascular injury.

Cat. No.

AT0047

CAS No.

1407495-02-6

Bococizumab

Synonyms: PF-04950615; RN316

Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a regulator of LDL receptor degradation. By reducing circulating LDL cholesterol, Bococizumab is used in preclinical studies of hypercholesterolemia and cardiovascular risk reduction.

Cat. No.

AT0068

CAS No.

1318075-13-6

Simtuzumab

Synonyms: AB 0024; GS 6624

Simtuzumab (AB 0024; GS 6624) is a monoclonal antibody specifically targeting Lysyl Oxidase-Like 2 (LOXL2). This antibody is utilized in the investigation of primary sclerosing cholangitis (PSC), providing a valuable tool for understanding the pathophysiological mechanisms underlying this condition.

Cat. No.

AT0081

CAS No.

2988795-75-9

Baloncibart

Baloncibart is a human monoclonal antibody of the IgG4 kappa subclass, specifically designed to target the Natriuretic Peptide Receptor A (NPR1). This antibody serves as a precise tool for the modulation and study of NPR1 receptor functions, which are crucial in various physiological processes including blood pressure regulation and fluid balance. For rigorous experimental control, it is paired with a corresponding isotype control, Human IgG4 (S228P) kappa, ensuring accurate assessment of antibody specificity and performance in research applications.

Cat. No.

AT0087

CAS No.

615258-40-7

Denosumab

Synonyms: AMG-162

Denosumab is a human monoclonal antibody specifically designed to target and bind to the receptor activator of nuclear factor kappa-B ligand (RANKL) with a dissociation constant (K_D) of 0.003 nM for human RANKL. By inhibiting the interaction between RANKL and its receptor, RANK, Denosumab effectively blocks the NF-κB signaling pathway, which is crucial in the regulation of bone metabolism and immune responses. This inhibition prevents bone resorption, a key factor in various bone diseases and disorders. Additionally, Denosumab has been observed to promote proliferation and spermatogenesis. This antibody is particularly useful in research focused on bone density regulation, osteoporosis, and related bone health studies.

Cat. No.

AT0100

CAS No.

2225109-03-3

Tafolecimab

Synonyms: IBI-306

Tafolecimab (IBI-306) is a human IgG2 monoclonal antibody designed to specifically target and bind to proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9, Tafolecimab effectively inhibits PCSK9-mediated endocytosis of low-density lipoprotein (LDL) receptors, thereby enhancing the clearance of LDL cholesterol (LDL-C) from the bloodstream. This mechanism leads to a significant reduction in LDL-C levels, making Tafolecimab a valuable tool for research into hypercholesterolemia and potential therapeutic interventions.

Cat. No.

AT0101

CAS No.

2361290-85-7

Recaticimab

Synonyms: SHR-1209

Recaticimab (SHR-1209) is a humanized monoclonal antibody that is orally active and selectively targets proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9 with high affinity, Recaticimab effectively increases the expression of low-density lipoprotein receptors (LDLR) on hepatocyte surfaces, subsequently leading to a reduction in plasma low-density lipoprotein cholesterol (LDL-C) levels. This antibody is particularly valuable for research focused on hypercholesterolemia and hyperlipidemia, offering a promising tool for investigating the regulation and management of cholesterol levels.

Cat. No.

AT0145

Anti-TSHR Antibody (M22)

Anti-TSHR Antibody (M22) is a humanized IgG1 kappa monoclonal antibody designed to specifically target the thyrotropin receptor (TSHR). This antibody effectively inhibits the interaction between thyroid-stimulating hormone (TSH) and its receptor, TSHR, thereby modulating receptor activity. For accurate experimental control, it is recommended to use Human IgG1 kappa Isotype Control. This product is ideal for research applications focusing on thyroid function and autoimmune thyroid disorders.

Cat. No.

AT0181

CAS No.

2725863-34-1

Zeleciment

Zeleciment is a monoclonal antibody of the IgG1κ isotype, specifically targeting the transferrin receptor (TFRC). This antibody binds with high specificity to TFRC, a key membrane protein involved in iron uptake and regulation, making it an essential tool for research into cellular iron metabolism, cancer biology, and related therapeutic areas.

Cat. No.

AT0275

Anti-TSHR Antibody (K1-70)

Synonyms: K1-70

The Anti-TSHR Antibody (K1-70) is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the Thyroid Stimulating Hormone Receptor (TSHR), making it an essential tool for research in thyroid function and autoimmune thyroid diseases. This antibody is comprised of a human IgG1 heavy chain and a human lambda light chain, and has a predicted molecular weight of 143.54 kDa. For experiments requiring an isotype control, the Human IgG1 kappa, Isotype Control is recommended to accurately assess the specificity and binding characteristics of the Anti-TSHR Antibody (K1-70).

Cat. No.

AT0346

CAS No.

2769700-97-0

Cibotercept

Cibotercept is a monoclonal antibody designed to target and inhibit the activity of MSTN (Myostatin), INHBA (Inhibin Beta A), and GDF11 (Growth Differentiation Factor 11). This antibody is engineered for high specificity and affinity, making it ideal for research applications focused on muscle growth, regulation, and related signaling pathways.

Cat. No.

AT0347

Anti-ANGPTL4 Antibody

Cat. No.

AT0367

CAS No.

2845128-05-2

Vixticibart

Vixticibart is a human monoclonal antibody of the IgG4κ subtype, specifically targeting NPR1. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control.

Cat. No.

AT0387

CAS No.

2410976-61-1

Ersodetug

Ersodetug is a human IgG2 κ monoclonal antibody targeting the insulin receptor (INSR). For experimental control purposes, it is recommended to use Human IgG2 kappa as an isotype control.

Cat. No.

AT0405

CAS No.

1245916-14-6

Alirocumab

Synonyms: REGN 727; SAR 236553

Alirocumab is a human monoclonal antibody that targets and inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to PCSK9, Alirocumab enhances the liver's capacity to bind and clear low-density lipoprotein cholesterol (LDL-C) from the bloodstream, thereby significantly reducing circulating levels of LDL-C. Additionally, Alirocumab modulates various inflammatory pathways, including the reduction of NLRP3 inflammasome activity and regulation of the Nrf2/HO-1, HMGB1/NF-κB, and Fractalkine/CX3CR1 signaling pathways. These mechanisms contribute to its therapeutic effects in improving atherosclerosis and reducing inflammation. Alirocumab is primarily used in research focused on lipid metabolism disorders, cardiovascular diseases, and inflammatory response modulation.

Cat. No.

AT0425

Anti-PCSK9 Antibody

The Anti-PCSK9 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 145 kDa. For isotype control, the Human IgG1 kappa, Isotype Control is recommended. This antibody is ideal for research focused on the regulation of LDL cholesterol levels and cardiovascular disease mechanisms.

Cat. No.

AT0429

CAS No.

2761478-99-1

Maridebart

Synonyms: AMG133 antibody

Maridebart is a monoclonal antibody of the human immunoglobulin G1-kappa subclass, specifically targeting the gastric inhibitory polypeptide receptor (GIPR). This antibody binds selectively to GIPR, a receptor involved in glucose homeostasis and lipid metabolism, making it a valuable tool for research in metabolic disorders and diabetes.

Cat. No.

AT0524

CAS No.

2304800-90-4

Ebronucimab

Synonyms: AK102

Ebronucimab (AK102) is a recombinant IgG1-λ2 monoclonal antibody specifically designed to target Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). This antibody is produced in Chinese Hamster Ovary (CHO) DG44 cells, ensuring high fidelity and consistency in antibody structure and function. Ebronucimab binds to PCSK9, inhibiting its ability to interact with the low-density lipoprotein receptor (LDLR), thereby modulating cholesterol metabolism. This makes it a valuable tool for research in cardiovascular diseases, lipid metabolism, and therapeutic development.

Cat. No.

AT0538

CAS No.

2922218-19-5

Emugrobart

Emugrobart is a humanized IgG1κ antibody that specifically targets GDF8 (Growth Differentiation Factor 8). For experimental control purposes, the recommended isotype control is Human IgG1 kappa Isotype Control. This antibody is designed for precise specificity and is ideal for research focusing on muscle growth and differentiation pathways.

Cat. No.

AT0546

LY2787106

LY2787106 is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Hepcidin, also known as HAMP. This antibody is comprised of a human IgG4SP subtype heavy chain and a human kappa (huκ) light chain, with an estimated molecular weight of 144.2 kDa. For experimental control purposes, the appropriate isotype control is Human IgG4 kappa.

Cat. No.

AT0555

Anti-ANGPTL8 Antibody

Cat. No.

AT0666

Anti-CD71/TfR1 Antibody

Synonyms: JR-141 antibody (uncoupled from iduronate 2-sulfatase

The Anti-CD71/TfR1 Antibody, also known as JR-141 antibody, is a humanized monoclonal antibody targeting the human transferrin receptor (CD71; TfR1). This antibody is the unmodified, antibody-only component of the fusion protein Pabinafusp alfa, which is utilized in therapeutic applications. For experimental controls, it is recommended to use Human IgG1 kappa as an isotype control. This product is essential for research focusing on iron metabolism, cellular iron uptake, and the pathophysiology of related disorders.